文献速递淋巴瘤

全基因组测序揭示淋巴瘤抗CD19 CAR T细胞治疗失败的复杂基因组特征

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
PubMed 文献 · Blood · 2022-01-01

该研究对49例接受CAR-19治疗的大B细胞淋巴瘤患者的51份肿瘤样本进行全基因组测序,发现治疗前存在复杂结构变异、APOBEC突变特征和活性氧所致基因组损伤可预测CAR-19耐药;复发性3p21.31染色体缺失(含RHOA抑癌基因)在治疗失败患者中显著富集;治疗前CD19表达降低或单等位缺失不影响缓解。

要点

  • 治疗前复杂结构变异、APOBEC突变特征和活性氧基因组损伤可预测CAR-19耐药。
  • 含RHOA抑癌基因的3p21.31染色体缺失在CAR T治疗失败患者中显著富集。
  • 治疗前CD19表达降低或单等位缺失不影响CAR-19治疗缓解。

核心结论

  • 肿瘤内在基因组改变是大B细胞淋巴瘤CAR-19疗效与耐药复杂 interplay 中的关键因素。

研究设计与样本

  • 研究对49例接受CAR-19治疗的大B细胞淋巴瘤患者的51份肿瘤样本进行全基因组测序。

主要发现

  • 治疗前存在复杂结构变异、APOBEC突变特征和活性氧所致基因组损伤可预测CAR-19耐药。
  • 含RHOA抑癌基因的复发性3p21.31染色体缺失在CAR T细胞治疗失败患者中显著富集。
  • 治疗前CD19表达降低或单等位缺失不影响治疗缓解。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking immunotherapies approved for use against large B-cell lymphomas. Although host inflammatory and tumor microenvironmental markers associate with efficacy and resistance, the tumor-intrinsic alterations underlying these phenomena remain undefined. CD19 mutations associate with resistance but are uncommon, and most patients with relapsed disease retain expression of the wild-type receptor, implicating other genomic mechanisms. We therefore leveraged the comprehensive resolution of whole-genome sequencing to assess 51 tumor samples from 49 patients with CAR-19-treated large B-cell lymphoma. We found that the pretreatment presence of complex structural variants, APOBEC mutational signatures, and genomic damage from reactive oxygen species predict CAR-19 resistance. In addition, the recurrent 3p21.31 chromosomal deletion containing the RHOA tumor suppressor was strongly enriched in patients for whom CAR T-cell therapy failed. Pretreatment reduced expression or monoallelic loss of CD19 did not affect responses, suggesting CAR-19 therapy success and resistance are related to multiple mechanisms. Our study showed that tumor-intrinsic genomic alterations are key among the complex interplay of factors that underlie CAR-19 efficacy and resistance for large B-cell lymphomas.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022. PMID: 35476848. doi:10.1182/blood.2021015008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。